MET-097i
Phase 2- Indications
- Obesity
Company intelligence / Profile preview
Metsera
New York, New York, United Statesmetsera.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
MET-097i demonstrated 7.5% weight loss from baseline at day 36 in Phase I/II trials, and up to 11.3% weight loss after 12 weeks in Phase 2a trials. The drug has a half-life of about 15-16 days, which the company claims is the longest of any NuSH analog peptide in development.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- GLP-1 receptor agonist peptidesinjectable peptidesoral peptidesamylin analog peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Amneal Pharmaceuticals (supply partnership)
Beyond the preview
Go deeper on Metsera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metsera.